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Treatment of primary myelofibrosis
Primer miyelofibroz tedavisi
To the Editor,
I have read with interest the presentation of three adult 
patients with primary myelofibrosis by Kar et al. in the recent 
issue of the journal [1]. The authors, without mentioning dose 
schedule, stated that parenteral and oral methylprednisolone 
was used in their patients.
Although our cases of primary myelofibrosis (PM) were not 
included in Kar et al.’s review, we were the first to successfully 
treat those patients, beginning in 1980, with megadose 
methylprednisolone (MDMP) [2-5]. Five children and four 
adult patients (a 60- year-old woman was not reported) with 
PM were all treated with MDMP (daily, 30 mg/kg for 3 days, 
followed by 20 mg/kg for 4 days, and then by 10, 5, 2 mg/kg 
doses, each dose given 1 week, continued with 1 mg/kg dose 
until hemoglobin (Hb) level reached 12 g/dl). Each dose was 
given within 5 to 10 minutes, intravenously earlier and orally 
recently. Each dose was given before 9 a.m., preferentially 
between 5 and 6 a.m.
It must be emphasized that MDMP treatment should not 
be compared with conventional prednisone administration (2 
mg/kg, usually divided into 2 or 4 doses). Despite elevation in 
Hb level in the authors’ patients, correction of the myelofibrotic 
process was not investigated by the authors. In 6 of our 9 
patients, normalization of bone marrow was shown by 
bone marrow biopsy. During the 6-year follow-up period, no 
recurrences were observed in our patients.
Increased reticulin score of the bone marrow was 
mentioned by the authors. I would like to call attention to the 
fact that the presence of increased collagen and osteoblasts 
in the bone marrow as well as increased number of white cells 
and megakaryocyte precursors in the peripheral blood were 
more informative for the diagnosis [6.7].
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Author Reply
Dear Editor,
We would thank Prof. Özsoylu for critically evaluating our 
paper and giving some valuable comments.The review of 
cases in our paper specifically refers to the distinct entity of 
primary autoimmune myelofibrosis reported in the literature. 
In this study we have not included cases of idiopathic 
myelofibrosis and hence references quoted by Prof. Özsoylu 
have not been mentioned. 
The patients 1 and 2 received iv methyl prednisolone 1g 
IV OD x 3 days followed by wysolone 50 mg PO. At 5 months 
and one year follow up, there was improvement in cytopenias 
and spleen size was regressed. The patient 3 received oral 
steroids (dose 1mg/kg/day). At one year of follow up the 
total leucocyte counts and hemoglobin were normal and 
paravertebral mass had regressed. However, spleen was 
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Fatih University Medical School Hospital, Ankara, Turkeypalpable 2 cm. below costal margin. Unfortunately, all three patients 
had a short period of follow up and thus a repeat trephine biopsy 
could not be performed to assess the marrow fibrosis.
As regards to increased collagen fibrosis and osteosclerosis, that 
would indicate progression of the same disease process to more 
advanced stages. None of our cases showed osteosclerosis and 
there was absence of significant leukoerythroblastosis as opposed to 
cases idiopathic myelofibrosis.
Sincerely,
Seema Tyagi MD.
Associate Professor 
Department of Hematology
All India Institute of Medical Sciences,
New Delhi - 110029, India
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